Recent report by Argonaut Research, increases their valuation from $0.14 to $0.225.
Excerpt:
"Our valuation climbs from $0.140 to $0.225 for the following reasons:
We assume the likelihood of potential cash flows associated with BTX 1801 increases to 24.4% (previously 16.3%) following the successful Phase 2a study. This is based on prior broad analysis of the likelihood of FDA studies progressing through clinical trial phases to commercialisation. All other assumptions regarding potential market size and possible BTX 1801 penetration are unchanged on prior."
Recent report by Argonaut Research, increases their valuation...
-
- There are more pages in this discussion • 489 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.015(4.11%) |
Mkt cap ! $559.1M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 36.5¢ | 34.5¢ | $1.891M | 5.360M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 704602 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 306733 | 9 |
View Market Depth
| Last trade - 11.52am 26/06/2024 (20 minute delay) ? |
| BOT (ASX) Chart |